Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Havens Clark"'
Autor:
Cynthia M. Simbulan-Rosenthal, Yogameenakshi Haribabu, Sahar Vakili, Li-Wei Kuo, Havens Clark, Ryan Dougherty, Ryyan Alobaidi, Bonnie Carney, Peter Sykora, Dean S. Rosenthal
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 4, p 2333 (2022)
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MIC) implicated in tumorigenesis, invasion, and drug resistance, and is characterized by the elevated expression of stem cell markers, including CD133. The siRNA knockdo
Externí odkaz:
https://doaj.org/article/d21219d8996e43a393e52546e8cf5267
Autor:
Hilary Whitworth, Helen Havens Clark, Rebecca A. Hubbard, Char Witmer, Charles E. Leonard, Leslie Raffini
Publikováno v:
Journal of Thrombosis and Haemostasis. 21:47-56
Publikováno v:
Blood
Central venous catheters (CVC) are the most significant risk factor for pediatric venous thromboembolism (VTE). After an index CVC-associated VTE (CVC-VTE), the role of secondary prophylaxis for subsequent CVC placement is uncertain. Aims of this sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023f05760b41343709ac02bbffc54f9f
https://europepmc.org/articles/PMC8777201/
https://europepmc.org/articles/PMC8777201/
Autor:
Sahar Vakili, Cynthia M. Simbulan-Rosenthal, Anirudh Gaur, Leala Aljehane, Qing Qin, Maryam AbdusSamad, Kumari Karna, Dean S. Rosenthal, Ryan Dougherty, Li-Wei Kuo, Havens Clark, Edward C. McCarron, Hengbo Zhou
Publikováno v:
Journal of Oncology, Vol 2019 (2019)
Journal of Oncology
Journal of Oncology
FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF inhibitor dabrafenib for BRAFV600 mutations. NRAS-mutated cell lines are also sensitive to MEK inhibitionin vitro, and NRAS-mut
Autor:
HAVENS, CLARK T.
Publikováno v:
Milwaukee Monthly Magazine; Jun1873, Vol. 5 Issue 30, p253-253, 1/4p
Autor:
HAVENS, CLARK T.
Publikováno v:
Milwaukee Monthly Magazine; May1873, Vol. 5 Issue 29, p193-193, 1/2p